H.R. 27 · 119th Congress

HALT Fentanyl Act

Introduced on Jan 3, 2025 by H. Morgan Griffith (R-VA-9). 61 cosponsors, 2 of them from another party. Latest action (Feb 10, 2025): Received in the Senate and Read twice and referred to the Committee on the Judiciary.

Stage
Passed one chamber
Introduced
Jan 3, 2025
Cosponsors
61
2 from the other party
Policy area
Crime and Law Enforcement

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.

Subjects

  • Administrative law and regulatory procedures
  • Department of Justice
  • Drug trafficking and controlled substances
  • Licensing and registrations
  • Research administration and funding

Summary

By the Congressional Research Service (Introduced in House, Jan 3, 2025). Public domain.

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act

This bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.

Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).

Additionally, the bill establishes a new, alternative registration process for certain schedule I research.

The bill also makes several other changes to registration requirements for conducting research with controlled substances, including

  • permitting a single registration for related research sites in certain circumstances,
  • waiving the requirement for a new inspection in certain situations, and
  • allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.

Finally, the bill expresses the sense that Congress agrees with the interpretation of Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

H. Morgan GriffithR-VA-9Sponsor

Democrats · 2

Independents · 1

Republicans · 58

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

  1. Feb 6, 2025· House· Amendments· Failed 182–226
  2. Feb 6, 2025· House· Passage· Passed 312–108

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Jan 3, 2025Introduced in House
  2. Jan 3, 2025Introduced in House
  3. Jan 3, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Jan 3, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  5. Feb 4, 2025 · HouseRules Committee Resolution H. Res. 93 Reported to House. Rule provides for consideration of H.R. 27 with 1 hour of general debate. Motion to recommit allowed. The resolution makes in order only the further amendment printed in Part B of the Rules Committee report.
  6. Feb 5, 2025 · HouseRule H. Res. 93 passed House.
  7. Feb 6, 2025 · HouseConsidered under the provisions of rule H. Res. 93. (consideration: CR H520-533)
  8. Feb 6, 2025 · HouseRule provides for consideration of H.R. 27 with 1 hour of general debate. Motion to recommit allowed. The resolution makes in order only the further amendment printed in Part B of the Rules Committee report.
  9. Feb 6, 2025 · HouseDEBATE - The House proceeded with one hour of debate on H.R. 27.
  10. Feb 6, 2025 · HouseDEBATE - Pursuant to the provisions of H. Res. 93, the House proceeded with 10 minutes of debate on the Trahan amendment No. 2.
  11. Feb 6, 2025 · HousePOSTPONED PROCEEDINGS - At the conclusion of debate on the Trahan amendment No. 2, the Chair put the question on agreeing to the amendment and by voice vote, announced that the noes prevailed. Mrs. Trahan demanded the yeas and nays and the Chair postponed further proceeding until a time to be announced.
  12. Feb 6, 2025 · HouseConsidered as unfinished business. (consideration: CR H533-535)
  13. Feb 6, 2025Passed/agreed to in House: On passage Passed by the Yeas and Nays: 312 - 108 (Roll no. 33). (text: CR H520-522)House · Roll call 33
  14. Feb 6, 2025 · HouseOn passage Passed by the Yeas and Nays: 312 - 108 (Roll no. 33). (text: CR H520-522)House · Roll call 33
  15. Feb 6, 2025 · HouseMotion to reconsider laid on the table Agreed to without objection.
  16. Feb 10, 2025 · SenateReceived in the Senate and Read twice and referred to the Committee on the Judiciary.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. AMERICAN SOCIETY OF ANESTHESIOLOGISTS6 reports
    $1.5M reported (all issues)
  2. DUE PROCESS INSTITUTE6 reports
    $160K reported (all issues)
  3. National Fraternal Order of Police5 reports
    $500K reported (all issues)
  4. National Troopers Coalition4 reports
    $40K reported (all issues)
  5. Peace Officers Research Association of California4 reports
    $200K reported (all issues)
  6. Indivior Inc3 reports
    $730K reported (all issues)Federal contractor: INDIVIOR INC.AI match · 100%
  7. ACT FOR AMERICA2 reports
    $20K reported (all issues)
  8. College on Problems of Drug Dependence2 reports
    $40K reported (all issues)
  9. DRUG POLICY ALLIANCE2 reports
    $31.4K reported (all issues)
  10. Leadership Conference on Civil and Human Rights2 reports
    $1.1M reported (all issues)
  11. NATIONAL COUNCIL FOR BEHAVIORAL HEALTH2 reports
    $291.6K reported (all issues)Federal contractor: NATIONAL COUNCIL FOR BEHAVIORAL HEALTH$4.3M in contracts, FY2026AI match · 100%
  12. National Association of Pediatric Nurse Practitioners2 reports
    $48K reported (all issues)
  13. AMERICAN BAR ASSOCIATION1 report
    $280K reported (all issues)Federal contractor: AMERICAN BAR ASSOCIATIONAI match · 100%
  14. AMERICAN SOCIETY OF ADDICTION MEDICINE1 report
    $50K reported (all issues)
  15. American Civil Liberties Union1 report
    $560K reported (all issues)
  16. American Medical Association1 report
    $8M reported (all issues)Federal contractor: AMERICAN MEDICAL ASSOCIATION$371K in contracts, FY2026AI match · 99%
  17. Center for American Progress Action Fund1 report
    $30K reported (all issues)
  18. National Association of Assistant United States Attorneys1 report
    $10K reported (all issues)
  19. National Legal Aid and Defender Association1 report
  20. Sergeants Benevolent Association of New York City1 report
    $30K reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 5, 2026 · loaded Oct 5, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.